RT Journal Article
SR Electronic
T1 Acute Endotheliitis (Type 3 Hypersensitivity Vasculitis) in Ten COVID-19 Autopsy Brains
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.16.21249632
DO 10.1101/2021.01.16.21249632
A1 Rhodes, Roy H.
A1 Love, Gordon L.
A1 Da Silva Lameira, Fernanda
A1 Sadough, Maryam Shahmirzadi
A1 Fox, Sharon E.
A1 Heide, Richard S. Vander
YR 2021
UL http://medrxiv.org/content/early/2021/01/18/2021.01.16.21249632.abstract
AB Central nervous system (CNS) involvement in COVID-19 may occur through direct SARS-CoV-2 invasion through peripheral or cranial nerves or through vascular endothelial cell infection. The renin-angiotensin system may play a major part in CNS morbidity. Effects of hypoxia have also been implicated in CNS lesions in COVID-19. This communication reports on ten consecutive autopsies of individuals with death due to COVID-19 with decedent survival ranging from 30 minutes to 84 days after admission. All ten brains examined had neutrophilic microvascular endotheliitis present in variable amounts and variably distributed. Importantly, this acute stage of type 3 hypersensitivity vasculitis can be followed by fibrinoid necrosis and inner vascular wall sclerosis, but these later stages were not found. These results suggest that a vasculitis with autoimmune features occurred in all ten patients. It is possible that viral antigen in or on microvascular walls or other antigen-antibody complexes occurred in all ten patients proximate to death as a form of autoimmune vasculitis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementNone. No third party participation of any kind, and no external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:These studies were determined to be exempt by the IRB at Louisiana State University Health Sciences Center, New Orleans.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the manuscript are supported by completed and signed University Medical Center-New Orleans autopsy files.